Estatinas:Características y Efectos sobre el Control Lipídico en el Niño y Adolescente Obeso

  1. E. González Jiménez 1
  2. J. Álvarez Ferre 2
  1. 1 Departamento de Enfermería. Facultad de Ciencias de la Salud. Universidad de Granada. Granada (España)
  2. 2 Unidad de Hospitalización Crónica. Hospital Universitario San Rafael. Granada (España)
Revista:
Revista Clínica de Medicina de Familia

ISSN: 2386-8201

Año de publicación: 2011

Volumen: 4

Número: 1

Páginas: 69-75

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Revista Clínica de Medicina de Familia

Resumen

La obesidad en niños y adolescentes representa un problema emergente de salud pública, siendo el trastorno nutricional y metabólico más prevalente en los países desarrollados. Paralelo a este incremento de obesidad, han hecho su aparición dislipemias a edades cada vez más tempranas. En la última década se han producido novedosos avances en el tratamiento de estas alteraciones lipídicas, fundamentalmente debido a la introducción de las estatinas en su terapia. Su utilidad y eficacia ampliamente demostrada en adultos parece ser igualmente aplicable en el tratamiento de las hipercolesterolemias durante la infancia. En la actualidad son seis ya las estatinas utilizadas en población infantil, habiendo sido analizada su actividad en niños y jóvenes a través de ensayos clínicos, en los que se concluye su eficacia y seguridad para reducir las concentraciones tanto de colesterol total como de colesterol en lipoproteínas de baja densidad (c-LDL) en sangre. El objetivo de este trabajo ha sido ofrecer una revisión actualizada sobre las características de éstas y sus efectos en la mejora clínica de los niveles de lípidos en sangre en niños y adolescentes con sobrepeso y obesidad.

Referencias bibliográficas

  • American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992; 89:525-84.
  • Amundsen AL, Ose L, Nenseter MS, Ntanios FY. Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am J Clin Nutr. 2002; 76:338-44.
  • Berenson GS, Srinvasan SR, Bao W. For the Bogalusa Herat Study Association between múltiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998; 338:1650-56.
  • Celermajer DS, Sorensen KE, Gooch VM. Non invasive detection of endothelial dysfunction in children and adults at risck of atherosclerosis. Lancet. 1992; 340:1111-15.
  • Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004; 173:55-68.
  • Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39:257-65.
  • Daniels SR, Greer FR; Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008; 122:198-208.
  • De Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJP, Stroes ESG. Family history of cardiovascular events and endothelial dysfunction in children with hypercholesterolemia. Atherosclerosis. 2002; 163:193-97.
  • De Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized, double-blind, placebo- controlled trial with simvastatin. Circulation. 2002; 106:2231-37.
  • Ferranti S, Ludwig DS. Storm over statins. The controversy surrounding pharmacologic treatment of children. N Eng J Med. 2009; 359:1309-12.
  • Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductasa. Science. 2001; 292:1160.
  • Jenkins, DJ, Kendall, CW, Faulkner, D. y cols. A dietary portfolio approach to cholesterol reduction: Combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism. 2002; 51:1596-1604.
  • Ketomaki A, Gylling H, Miettinen TA. Effects of plant stanol and sterol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous subject. J Lab Clin Med. 2004; 143:255-62.
  • Kochhar SP. Influence of processing on sterols of edible vegetable oils. Prog Lipid Res. 1983; 22:161-88.
  • Kwiterovich PO. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab. 2008; 93:4200-09.
  • Li S, Chen W, Srinivasav SR, Bond MG, Tang R, Urbina EM, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: The Bogalusa Heart Study. JAMA. 2003; 290:2271-76.
  • Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidake H, Kojima H, et al. Two genes that map to STSL locus cause sitosterolemia: Genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet. 2001; 69:278-90.
  • McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatinin children and adolescents with familial hipercolesterolemia or severe hyperlipidemia: A multicenter, randomized, placebo-controlled trial. J Pediatr. 2003; 142: 74-80.
  • McCrindle BW. Hyperlipidemia in children. Thromb Res. 2006; 118:49-58.
  • Meyer AA, Kundt G, Steiner M, Schuff-Werner P, Kienast W. Impaired flow-mediated vasodilation, carotid artery intimamedia thickening, and elevated endothelial plasma markers in obese children: the impact of cardiovascular risk factors. Pediatrics. 2006; 117:1560-67.
  • Miettinen TA, Tilvis RS, Kesaniemi YA. Serum plant sterols and colesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol. 1990; 131:20-31.
  • Nair PP, Turjman N, Kessie G, Calkins B, Goodman GT, Davidovitz H et al. Diet, nutrition intake, and metabolismo in populations at high and low risk for colon cancer. Dietary cholesterol, beta-sitosterol, and stigmasterol. Am J Clin Nutr. 1984; 40 (Suppl. 4):927-30.
  • Newman WP, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerotisis: The Bogalusa Heart Study. N Engl J Med. 1986; 314:13844.
  • Ostlund RE, Racette SB, Okeke A, Stenson WF. Phytosterols that are naturally present in commercial corn oil significantly reduce cholesterol absorption in humans. Am J Clin Nutr. 2002; 75:1000-4. Ostlund RE. Phytosterols in human nutrition. Annu Rev Nutr. 2002; 22:533-49.
  • Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis. 2002; 160:41.
  • Pollak OJ. Reduction of blood cholesterol in man. Circulation. 1953; 7:702-6.
  • Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson SK, et al. Human cholesterol 7 alpha hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002; 110:109-17.
  • Quyyumi AA. Endothelial functions on health and disease: new insigths into the genesis of cardiovascular disease. Am J Med. 1998; 105:325-95.
  • Relationship of atherosclerosis in young men to serum lipoprotein colesterol concentrations and smoking: A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990; 264:3018-24.
  • Rodenburg J, Visser MN, Trip MD, Wiegman A, Bakker HD, Kastelein JJP. The spectrum of statin therapy in hyperlipidemic children. Seminars in Vascular Medicine. 2004; 4:313-20.
  • Sanders, DJ, Minter, HJ, Howes, D, Hepburn, PA. The safe ty evaluation of phytosterol esters. Part 6. The comparative absorption and tissue distribution of phytosterols in the rat. Food Chem Toxicol. 2000; 38:485-91.
  • Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris, Pears J, et al. Safety of rosuvastatin. Am J Cardiol. 2004; 94:882-88.
  • Skilton MR, Celermajer DS. Endothelial dysfunction and arterial abnormalities in childhood obesity. Int J Obes. 2006; 30:1041-49.
  • Spiotta RT, Luma GB. Evaluating obesity and cardiovascular risk factors in children and adolescents. Am Fam Physician. 2008; 78(9):1052-58.
  • Tapia L, Picazo B, Ruiz C. Uso de estatinas durante la infancia. An Pediatr (Barc). 2008; 68(4):385-92.
  • Tojo Sierra R, Leis Trabazo R. La obesidad, un problema emergente en pediatría Conferencia inaugural del VIII Congreso Nacional de la Sociedad Española de Nutrición, Murcia, 24-27 de octubre de 2001. Nutr Hosp. 2002; 17: 75-9.
  • Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripuberal and prepuberal children with familial hypercholesterolemia. J Pediatr. 1996; 129:42-9.
  • Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000; 35:1-10.
  • Wiegman A, De Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolemia. Lancet. 2004; 363:369-70.
  • Wiegman A, Hutten BA, De Groot E, Rodenburg J, Bakker HD, Buller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial. JAMA. 2004; 292:331-7.
  • Woo KS, Chook P, Yu CW, et al. Overweight in children is associated with arterial endothelial dysfunction and intimamedia thickening. Int J Obes. 2004; 28:852-57.
Fuente de los datos: Dialnet